TABLE 10.1

Summary of different applications of Gag VLPs

Application

Target

Gag sequence

Antigen/cargo

Strategy

Cell line

Animal Model

Reference

HIV-1 Vaccines

HIV-1 pr55,

SIVmac239,

dGag

Env Variants gp120, gp140,

gp41, gp145

BEVS and TGE

Sf9, HEK 293F,

HEK 293 T,

COS, S2 cells

BALB/c mice,

C57BL/6 J, rabbit,

guinea pig, Rhesus

macaque, Chacma

baboon

Cervera, et.al. 2019

(review) [ 17]

Pseudotyped

Vaccines

Influenza

HIV-1 pr55

HA and NA (H1N1)

TGE +SGE

HEK 293 SF

cells

BALB/c mice

Venereo-Sanchez, et.

al 2016 [ 26]

FMDV

HIV-1 pr55

RVG carring G-H loop

TGE

HEK 293 SF

cells

BALB/c mice

Fontana, et al.

2021 [ 27]

Influenza

HIV-1

HA and NA (H1N1 &

H5N1)

TGE

HEK 293T cells BALB/c mice

Giles, et al. 2011[ 28]

and Carter, et al.

2016 [ 29]

Dengue

HIV-1 pr55

DIII-DENV1_RigE

BEVS

Sf9 cells

BALB/c mice

Chua, et al.

2013 [ 30]

West Nile

Virus

DIII-WNVKun_RigE

HPV

HIV-1

HPV-16 E7 and VSV-G

TGE+ Packaging

cell

gag-pol 293

GPR

packaging cells

C57BL/6 mice

Di Bonito, et al.

2009 [ 31]

Equine Herpes

Virus

HIV-1 b-p55

Truncated gp14

BEVS

High Five

BALB/c mice

Osterrieder, et al.

1995 [ 32]

Pseudorabies

HIV-1 pr55

gD

BEVS

Sf9 cells

Garnier, et al.

1995 [ 33]

(Continued)

Recombinant vaccines: Gag-based VLPs

243